Azer-cel Granted FDA Fast Track Designation in Blood Cancer
Filed with ASX · · 3 pages · English
Summary by 6ix AI
This designation is intended to expedite the development and review of therapies addressing serious conditions and supports Imugene's efforts to accelerate treatment timelines for patients. The therapy aims to overcome logistical challenges associated with traditional CAR T therapies by utilizing pre-manufactured donor T-cells for rapid treatment delivery.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Imugene
- S&P DJI Announces March 2025 Quarterly Rebalance
- Imugene Granted India Patent for Oncolytic Virotherapy CF33
- Imugene OnCARlytics Patent Allowance in China
- Azer-cel demonstrates two additional Complete Responses
- Imugene Receives A$20 million for Convertible Notes Issuance
Later from Imugene
- Notice of Extraordinary General Meeting/Proxy Form
- Two Additional Complete Responses in azer-cel Ph1b trial
- Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
- Imugene Completes $22.5M Placement and c.$15M SPP
- Imugene Capital Raising Presentation
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene